ABSTRACT
The perioperative morbidity of local radical transurethral resection performed in 103 patients with muscle-invasive bladder cancer (T2-T3a) was 20%, their mortality 1%. The three- and five-year survivals were 54% and 36%, respectively. Within 5 years after transurethral resection of primary tumours relapses were encountered in 46%, progression in 33% of the cases. The cause of death was tumour in 29% of the patients, and some other disease in 35%. The full thickness transurethral resection combined with adjuvant treatment may be an alternative to cystectomy in selected cases of T2-T3a bladder cancer.
Subject(s)
Urinary Bladder Neoplasms/surgery , Aged , Combined Modality Therapy , Female , Follow-Up Studies , Humans , Male , Muscles/pathology , Neoplasm Invasiveness , Neoplasm Recurrence, Local/epidemiology , Neoplasm Staging , Surgical Procedures, Operative/methods , Survival Rate , Urethra , Urinary Bladder Neoplasms/drug therapy , Urinary Bladder Neoplasms/mortality , Urinary Bladder Neoplasms/pathology , Urinary Bladder Neoplasms/radiotherapyABSTRACT
A total of 126 patients, whose superficial bladder tumours (Ta-Tl) had been removed by TUR, were subjected to local BCG therapy. Marked by frequent though mild side effects, they presented a significantly lower rate of tumour recurrence than the control group under exclusive TUR treatment. During a follow-up period of 3 years, 74% of the patients proved recurrence-free. BCG and Adriamycin were found largely similar in degree of effectiveness.